| Identification | Back Directory | [Name]
1,4-Oxazepin-5(2H)-one, 4-[3-[[2-[[2-ethyl-4-(4-methyl-1-piperazinyl)phenyl]amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]propyl]tetrahydro- | [CAS]
2543673-19-2 | [Synonyms]
SGR-1505/DCC3116
4-(3-((2-((2-ethyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,4-oxazepan-5-one
1,4-Oxazepin-5(2H)-one, 4-[3-[[2-[[2-ethyl-4-(4-methyl-1-piperazinyl)phenyl]amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]propyl]tetrahydro- | [Molecular Formula]
C26H36F3N7O2 | [MOL File]
2543673-19-2.mol | [Molecular Weight]
535.6 |
| Chemical Properties | Back Directory | [Boiling point ]
736.6±70.0 °C(Predicted) | [density ]
1.266±0.06 g/cm3(Predicted) | [form ]
Solid | [pka]
7.87±0.42(Predicted) | [color ]
Light brown to brown |
| Hazard Information | Back Directory | [Uses]
DCC-3116 is an orally active ULK1/2 inhibitor. DCC-3116 can promote autophagy in lung cancer cells by inhibiting KRASG12C signaling, thereby inhibiting the proliferation of lung cancer cells and exerting anti-cancer effects[1]. | [in vivo]
DCC-3116 (3 or 30 mg/kg/day for 56 days, p.o. and p.i.) alone or in combination with Sotorasib (HY-114277) can inhibit tumor growth in mouse models of NSCLC lung cancer[1].
| Animal Model: | mouse models of NSCLC lung cancer (adult mice were initiated between 6-8 weeks of age) [1] | | Dosage: | 3 or 30 mg/kg/day for 56 days | | Administration: | p.o. and p.i | | Result: | Inhibited mice tumor growth and improved mice survival rate, while significantly reducing mice body weight (>20%). |
| [IC 50]
ULK1; ULK2; KRas G12C | [References]
[1] Ghazi PC, et al. Inhibition of ULK1/2 and KRAS G12C controls tumor growth in preclinical models of lung cancer. bioRxiv [Preprint]. 2024 Feb 8:2024.02.06.579200. DOI:10.1101/2024.02.06.579200 |
|
|